MetaCap

Stoke Therapeutics (STOK) vs Zymeworks (ZYME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zymeworks (ZYME) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 8.8% versus a loss of 8.6%. Over five years, ZYME leads with a +34.1% price change compared with +6.8% for STOK. Zymeworks is the larger company by market cap ($1.81 billion vs $1.75 billion), about 1.0 times the size, while Stoke Therapeutics is growing revenue faster (+404.5% vs +38.9%).

Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -76.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

STOK-8.62%ZYME+8.83%
+34%+4%-26%
Nov 21, 20251 yearNov 20, 2026
STOK-3.56%ZYME+31.95%
+56%-19%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

STOK versus ZYME key metrics
MetricSTOKZYME
Share price$26.81$26.14
Market cap$1.75B$1.81B
1-day change-0.45%-2.68%
YTD return-15.53%-0.72%
1-year return-8.62%+8.83%
5-year return+6.77%+34.05%
P/E ratio (TTM)—49.32
Forward P/E—54.95
EPS (TTM)$-3.81$0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$184.42M$105.97M
Revenue growth (YoY)+404.50%+38.87%
Net income (latest FY)$-6.88M$-81.13M
Operating margin-11.16%-87.34%
Net margin-3.73%-76.56%
52-week high$40.22$31.97
52-week low$22.05$21.52
Distance from 52-week high-33.34%-18.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+73.00%+65.61%
Average volume1.02M1.09M
Shares outstanding65.41M68.70M
Employees170279
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZYME has outperformed STOK by 17.4 percentage points over the past year.
  • Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -76.6 cents for Zymeworks.
  • Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +38.87%).

About Stoke Therapeutics

STOK stock →

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees

About Zymeworks

ZYME stock →

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees

STOK vs ZYME FAQ

Which is bigger, Stoke Therapeutics or Zymeworks?

Zymeworks (ZYME) is larger, with a market capitalization of $1.81B compared with $1.75B for Stoke Therapeutics (STOK).

Which stock has performed better over the past year, STOK or ZYME?

ZYME returned +8.83% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.

Are Stoke Therapeutics and Zymeworks in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons